Track the medicine, not just the category
ADHD stock changes by drug, strength and pharmacy
Use this hub for the landscape, then check the exact medicine page before contacting your prescriber or pharmacy. If missing doses would affect work, driving, exams or care responsibilities, track the medicine for alerts.
If you have already run out, an emergency supply is usually faster than ringing round. Pharmacists cannot make an emergency supply of Schedule 1, 2 or 3 controlled drugs, such as ADHD stimulants, whoever asks (phenobarbital for epilepsy is the only exception): you need a new prescription, from your prescriber or through NHS 111. If you are still looking, check the national shortage status before you travel.
Get an emergency supply → Check stock & shortage status →On this page
The UK ADHD Medication Landscape
ADHD (Attention Deficit Hyperactivity Disorder) is one of the most commonly diagnosed neurodevelopmental conditions in the UK. The numbers tell a stark story:
- An estimated 1.9 million adults in the UK have ADHD, though the majority remain undiagnosed (ADHD UK, 2025)
- ADHD prescriptions in England rose by over 20% year-on-year from 2020 to 2024, according to NHSBSA prescribing data
- The number of ADHD medication items dispensed in England reached over 6 million per year by 2025, up from approximately 3.5 million in 2019
- Growth is driven by increased adult diagnosis rates, the NHS Right to Choose pathway enabling access to private ADHD assessments, and greater public awareness following media coverage and social media
- Meanwhile, manufacturing capacity has not kept pace — ADHD medications are Schedule 2 controlled drugs requiring Home Office raw material quotas, MHRA-inspected facilities, and regulatory approvals that prevent rapid scaling
The result: a widening gap between demand and supply that has persisted since late 2023 with no clear end date. Multiple manufacturers — including Takeda (Elvanse), Janssen (Concerta XL), and several generics producers — have increased production, but demand continues to grow faster than capacity comes online.
Quick Status: All ADHD Medications
New guide: ADHD medication stock checker — step-by-step help finding a pharmacy that can fill your prescription.
ADHD Medication Comparison Table
This table compares all ADHD medications available in the UK — their type, formulations, typical doses, and current supply status. This side-by-side view is unique to this hub page and is designed to help you and your prescriber evaluate alternatives quickly:
| Medication | Type | Formulations | Typical Adult Dose | Duration of Action | Official Shortage Status |
|---|---|---|---|---|---|
| Methylphenidate IR Ritalin, Medikinet |
Stimulant | Tablets 5mg, 10mg, 20mg | 10–60mg/day in divided doses | 3–4 hours | Generally available |
| Methylphenidate MR Concerta XL, Xaggitin XL, Matoride XL, Delmosart |
Stimulant | Tablets 18mg, 27mg, 36mg, 54mg | 18–54mg once daily | 10–12 hours | No current official active shortage |
| Methylphenidate MR capsules Equasym XL, Medikinet XL |
Stimulant | Capsules 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg | 10–60mg once daily | 8 hours (Equasym), 8 hours (Medikinet) | No current official active shortage |
| Lisdexamfetamine Elvanse, Elvanse Adult |
Stimulant (prodrug) | Capsules 20mg, 30mg, 40mg, 50mg, 60mg, 70mg | 30–70mg once daily | 13–14 hours | No current official active shortage |
| Dexamfetamine Amfexa, generic |
Stimulant | Tablets 5mg (generic), 5mg/10mg/20mg (Amfexa) | 5–20mg 2–3x daily | 4–6 hours | No current official active shortage |
| Atomoxetine Strattera, generics |
Non-stimulant (NRI) | Capsules 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg | 40–100mg once daily | 24 hours (continuous) | Available |
| Guanfacine Intuniv |
Non-stimulant (α2-agonist) | MR tablets 1mg, 2mg, 3mg, 4mg | 1–4mg once daily (children/adolescents) | 24 hours (continuous) | No current official active shortage |
Recent Supply Issues — Detail
Methylphenidate Prolonged-Release Tablets
Methylphenidate prolonged-release tablets
No current official shortage DHSC MSNMediWatch's latest official DHSC / NHSBSA data does not show methylphenidate prolonged-release tablets as a current active shortage. Historic disruption affected Concerta XL, Xaggitin XL, Matoride XL and Delmosart MR, so local pharmacy availability can still vary.
Methylphenidate is a first-line treatment for ADHD in both children and adults in the UK, as recommended by NICE NG87 and listed in the BNF. The prolonged-release formulations allow once-daily dosing, which is particularly important for school-age children and working adults who need consistent symptom control throughout the day. The intermittent regional disruptions mean stock may be available at one pharmacy but not another — it's worth phoning around before assuming it's completely unavailable.
Lisdexamfetamine (Elvanse)
Lisdexamfetamine (Elvanse) capsules
No current official shortage DHSC MSNMediWatch's latest official DHSC / NHSBSA data does not show Elvanse or lisdexamfetamine as a current active shortage. Historic constraints affected some strengths, so check the medicine page and your local pharmacy for the latest position.
Elvanse is a prodrug — it is converted to dexamfetamine in the body, giving a smoother onset and lower abuse potential than immediate-release stimulants. It has the longest duration of action of any ADHD stimulant (13–14 hours), making it popular for adults. The manufacturer, Takeda, has been actively working to increase production capacity.
Guanfacine (Intuniv)
Guanfacine (Intuniv) 2mg & 3mg modified-release tablets
No current official shortage DHSC MSNMediWatch's latest official DHSC / NHSBSA data does not show guanfacine as a current active shortage (checked 15 October 2026). An earlier DHSC notice, no longer active, said guanfacine 2mg and 3mg MR tablets had been out of stock and guanfacine 1mg and 4mg MR tablets could not support increased demand.
Guanfacine is a non-stimulant ADHD medication licensed in the UK for children and adolescents aged 6–17 years. It acts on alpha-2 adrenergic receptors in the prefrontal cortex. It's used when stimulants are unsuitable (e.g. tic disorders, anxiety, substance misuse risk) or as an add-on when stimulants alone don't provide adequate symptom control. It is not a controlled drug, which means prescriptions can be issued electronically and in larger quantities — and it has had supply problems of its own (see above).
Shortage Timeline: 2023–2026
Understanding when and how the ADHD shortage developed helps you understand why it's been so difficult to resolve:
First DHSC notifications
The DHSC issues Medicine Supply Notifications for methylphenidate prolonged-release tablets and lisdexamfetamine capsules. Initial notifications describe "intermittent supply issues" but the scale is not yet apparent. Pharmacies begin reporting difficulty sourcing stock.
Crisis escalates
Shortages spread across all methylphenidate MR brands and most Elvanse strengths. ADHD UK reports thousands of patients contacting them for help. Media coverage intensifies. The DHSC advises clinicians to delay initiating new patients on Elvanse and to consider alternative stimulants. Pharmacies report patients travelling over 50 miles to find stock.
Manufacturer commitments
Takeda (Elvanse) announces production capacity expansion. Generic methylphenidate manufacturers pledge increased output. The Home Office agrees to raise raw material quotas for controlled substance precursors. However, new capacity takes 6–12 months to come online.
Partial improvement
Elvanse supply gradually improves for 30mg, 50mg, and 70mg strengths. Methylphenidate MR remains problematic. Guanfacine 2mg and 3mg stock becomes unreliable. ADHD services resume cautious initiation of new Elvanse patients. Regional variation becomes pronounced — London and South East generally better stocked than Northern England, Wales, and Scotland.
New equilibrium
Supply improves across the board but doesn't fully normalise. ADHD prescriptions continue rising (new diagnoses still outpacing resolved ones). Manufacturers operate at increased capacity but demand keeps growing.
Ongoing steady state
The shortage enters a chronic phase — not acute crisis, but persistent undersupply. Certain strengths and brands remain intermittently unavailable. Patients have adapted (many switched medications during the crisis) but the system remains fragile. Any demand spike (e.g. new-year new-patient intake, university terms starting) can cause localised stock-outs.
Why Demand Has Outstripped Supply
The ADHD medication shortage is fundamentally a demand-side problem that the supply side cannot resolve quickly due to regulatory constraints on controlled drug manufacturing:
The Diagnosis Boom
- NHS Right to Choose: This pathway allows NHS patients to choose to be assessed by any qualified provider, including private ADHD assessment services like Psychiatry-UK. It dramatically shortened assessment wait times from 3–5 years in some areas to a few months, releasing a backlog of undiagnosed patients into the treatment pipeline.
- Private diagnosis growth: Dozens of private ADHD assessment services have launched since 2020, making diagnosis accessible to many who wouldn't have been assessed through traditional NHS pathways.
- Social media awareness: TikTok and other platforms dramatically increased public awareness of ADHD symptoms, particularly in adults who had never been assessed. While raising awareness is positive, it created an unprecedented spike in assessment requests.
- COVID-19 effect: Remote working and changed routines made many adults newly aware of attention difficulties they had previously managed through structure and routine.
The Manufacturing Bottleneck
- Schedule 2 controlled substances — Methylphenidate and amfetamine-based medications require Home Office quotas for raw material procurement, licensed manufacturing facilities with enhanced security, and additional regulatory oversight at every stage.
- Scaling takes time — A pharmaceutical manufacturer cannot simply produce more tablets next month. New production capacity requires facility modifications, regulatory inspections, stability testing, and batch validation — a process that typically takes 12–18 months minimum.
- Limited suppliers — The UK market for ADHD medications is concentrated among a small number of manufacturers. Elvanse is made exclusively by Takeda. Concerta XL by Janssen. There is no backup capacity if a single production line goes down.
Prescribing Data
NHSBSA data shows the scale of growth. Items dispensed for ADHD medications in England:
| Year | Approx. Items Dispensed (England) | Year-on-Year Change |
|---|---|---|
| 2019 | ~3.5 million | — |
| 2020 | ~3.8 million | +9% |
| 2021 | ~4.3 million | +13% |
| 2022 | ~5.0 million | +16% |
| 2023 | ~5.7 million | +14% |
| 2024 | ~6.2 million | +9% |
Source: NHSBSA prescription data (England only). Figures rounded. Includes all ADHD medications. Northern Ireland, Scotland, and Wales data published separately.
Can't Get Your ADHD Medication? Here's Exactly What To Do
This step-by-step flowchart guides you through every option, with branching paths depending on your situation:
Contact your pharmacy — ask specific questions
"Is this a local stock issue or a national shortage?" and "When is your next delivery from the wholesaler?" and "Can you check other branches in your chain?" A local stock-out may resolve in 24–48 hours.
Phone 3–5 other pharmacies
ADHD medication stock varies significantly between pharmacies and regions. Try independents, supermarket pharmacies (Asda, Tesco, Sainsbury's), and pharmacies in neighbouring towns. Ask specifically for your exact medication, strength, and brand.
Contact your ADHD prescriber (not just your GP)
Switching ADHD medications requires specialist input. Contact your psychiatrist, ADHD specialist nurse, or ADHD clinic directly. If you're under shared care, your specialist retains clinical responsibility for treatment decisions. Ask about: switching to an available strength, switching formulation (e.g. tablets to capsules), or switching drug class.
Emergency supply: what it can and cannot cover
Pharmacists cannot make an emergency supply of Schedule 2 ADHD stimulants (lisdexamfetamine, methylphenidate, dexamfetamine) at your request. Regulation 225 of the Human Medicines Regulations 2012 lets a pharmacist make an emergency supply at a patient's request, but excludes Schedule 1, 2 and 3 controlled drugs (phenobarbital for epilepsy is the only exception). You need a prescription, so contact your GP, your ADHD service or NHS 111.
Plan for ongoing supply
Sign up for MediWatch alerts for your specific medications. Order repeat prescriptions 7–10 days early. Ask your prescriber about a backup medication plan. Build a relationship with your pharmacist so they can flag supply issues proactively. Consider whether a different formulation or brand that's better supplied could work for you long-term.
⚠️ Important — Do Not Self-Manage ADHD Medication Changes
ADHD medications are controlled drugs (Schedule 2). Never adjust doses, split capsules, combine different medications, or switch brands without clinical guidance. The dose equivalences between different ADHD drugs are not straightforward — 20mg of methylphenidate is not the same as 20mg of lisdexamfetamine. Your prescriber needs to manage any switch.
Regional Variation
ADHD medication availability is not uniform across the UK. Based on patient reports, pharmacy surveys, and MediWatch data:
- London & South East: Generally better stocked due to higher pharmacy density and proximity to wholesale distribution centres. More options for patients to pharmacy-hop.
- Northern England: More persistent supply gaps reported, particularly in smaller towns. Fewer independent pharmacies means less wholesale diversity.
- Scotland: Additional supply challenges due to separate wholesaler arrangements and the Scottish Drug Tariff. Pharmacy density in rural areas (Highlands, Islands) makes shortages more impactful — fewer alternatives within practical travel distance.
- Wales: Similar pattern to Northern England. Welsh NHS structures mean slightly different response mechanisms.
- Northern Ireland: Cross-border effects — some patients report accessing medications in the Republic of Ireland, though this requires a separate prescription from an Irish-registered prescriber.
- University towns: Areas with large student populations (e.g. Manchester, Leeds, Bristol, Edinburgh) can see localised demand spikes at the start of term as students present prescriptions.
Support Organisations & Helplines
ADHD UK
The UK's leading ADHD charity. Provides support, medication shortage updates, and advocacy. Their shortage tracker is a valuable patient-reported resource alongside official DHSC data.
ADHD Foundation
Neurodiversity charity providing training, resources, and support for individuals, families, and professionals. Offers an ADHD helpline for medication and diagnostic queries.
AADD-UK (Adults with ADHD)
Specifically supports adults diagnosed with or seeking assessment for ADHD. Provides peer support groups, information resources, and a forum for sharing medication availability experiences.
NICE ADHD Guidelines (NG87)
The official clinical guideline for ADHD diagnosis and management. Useful to reference when discussing treatment options with your prescriber — it sets out the evidence for each medication and the recommended treatment pathway.
NHS 111
If you are in immediate need of medication and cannot access your prescriber, NHS 111 can help arrange emergency supplies or connect you with out-of-hours services.
Frequently Asked Questions
These FAQs cover hub-level questions about the ADHD shortage landscape. For medication-specific questions, see the individual medicine pages linked above.
GPs can prescribe some ADHD medications, but switching between ADHD drugs ideally requires specialist input. If you're on a shared care agreement, your GP manages repeat prescriptions under guidance from a psychiatrist. They can prescribe a different formulation of the same drug (e.g. switching from Concerta XL to Equasym XL, both methylphenidate) relatively easily. Switching drug class entirely — for example from methylphenidate to lisdexamfetamine — should involve your ADHD specialist. Contact your prescribing psychiatrist or ADHD service first. If wait times are long, ask your GP to make an urgent clinical query to the specialist team.
Under a shared care agreement, your specialist retains clinical responsibility for treatment decisions while your GP handles repeat prescriptions. If your medication is unavailable, your GP should contact your specialist for switching advice. To speed things up: contact your ADHD service directly, ask your GP to send an urgent clinical query via NHS e-Referral or email, and keep a record of when you last had medication so the specialist understands the urgency. Do not simply stop taking ADHD medication without medical advice.
Yes, shortages vary significantly by region. Urban areas with more pharmacies tend to have better availability. Rural areas and parts of Scotland, Wales, and Northern Ireland report more persistent gaps. Areas with large ADHD clinics or universities can see higher local demand. There is no official DHSC data on regional variation, but patient reports consistently show a postcode lottery. If your local pharmacy is consistently out of stock, try pharmacies in nearby towns or larger cities.
ADHD medicines had repeated UK supply pressure from late 2023, driven by increased demand, controlled-drug manufacturing constraints and Home Office quota limits. The latest official MediWatch data does not show a current active ADHD shortage row, but the category remains monitored because local availability can still vary.
Private prescriptions and online pharmacies source from the same UK wholesale supply chain, so they face the same shortages. A private prescription does not give you priority access. Some online pharmacies may occasionally have stock when local ones don't, but this isn't guaranteed. Be extremely cautious of any service offering ADHD medications that are "guaranteed available" — this may indicate unlicensed or counterfeit products. Always use pharmacies registered with the General Pharmaceutical Council (GPhC).
While medication is key to ADHD management for most people, non-pharmacological support can help bridge gaps: CBT adapted for ADHD, occupational therapy, ADHD coaching, structured routines, regular cardiovascular exercise (evidence shows it temporarily improves ADHD symptoms), and peer support through ADHD UK and the ADHD Foundation. Ask your GP for referrals to local ADHD support services. These are not replacements for medication, but can help manage symptoms during a shortage period.
The latest official MediWatch data does not show a current active ADHD shortage row. Historic supply pressure may still affect local availability, so patients should check the live medicine page and ask their pharmacist or prescriber before making treatment decisions.
Further Reading
- ADHD medication UK: types, how they work & live availability
- ADHD medication shortage UK 2026 — full timeline and analysis
- Elvanse shortage — what's happening and when supply normalises
- The ADHD medication crisis explained
- UK Medicine Shortages: The Complete Guide
- Your rights when medicines are unavailable
- Completely run out? How NHS 111 and pharmacists arrange an emergency supply
Related Condition Pages
Track your ADHD medications
Get a free shortage search the moment Elvanse, Concerta or any of your medications face supply issues
Sign up free — takes 30 seconds →This page is updated when new shortage data is published. Last checked: 12 November 2026, 06:18 UTC. This page is information, not medical advice — always speak to your GP, pharmacist or specialist team about your own medicines.